Q2 2026 Pediatrix Medical Group Inc Earnings Call Transcript
Key Points
- Reported another solid quarter with adjusted EBITDA of $76 million, in line with expectations.
- Same-unit revenue grew 2%, driven by strong RCM collections, favorable payer mix, and increased patient acuity.
- Payer mix improved by 135 basis points year-over-year and 120 basis points sequentially, showing resilience compared to peers.
- Repurchased nearly 2 million shares in Q2, reducing shares outstanding to 81 million from 87 million a year ago.
- Maintained a strong balance sheet with $289 million in cash, net debt of $295 million, and leverage just above 1x.
- Building a unique telehybrid medicine platform, combining teleservices with a physical footprint of over 170 MFMs and 360 NICUs.
- Salary growth remains controlled in a tight 3% to 3.5% band, with no signs of wage inflation accelerating.
- Actively exploring growth opportunities in women's and children's medicine, with interest from capital partners for JVs.
- Accounts receivable DSO improved by nearly four days year-over-year to 42.5 days, reflecting better cash collections.
- Reaffirmed full-year 2026 adjusted EBITDA outlook of $280 million to $300 million, with expectations of ratable performance in H2.
- Same-unit patient service volumes declined 2%, with NICU days down 3%, primarily in neonatology.
- Operating cash flow decreased to $126 million in Q2 from $138 million in the prior year, driven by changes in working capital.
- G&A expenses increased year-over-year due to executive transition-related costs, which are considered one-time-ish but elevated Q2.
- RCM collections tailwind, a key pricing driver, is expected to dissipate in the second half of 2026.
- Volume trends are expected to remain flat to slightly down for the full year, with no clear catalyst for near-term improvement.
- Practice-level salary and malpractice expenses increased year-over-year, adding cost pressure.
- D&A expense rose to $5.8 million from $5.3 million, reflecting higher capex and amortization from acquisitions.
- Management acknowledges uncertainty about future payer mix, noting they are not immune to potential negative shifts.
- Non-same-unit growth relies on acquisitions, but management notes pricing is fair and opportunities are selective.
- The company faces tough comps in neonatology volumes, making it difficult to predict a rebound in patient volumes.
Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q2 2026 Pediatrics Medical Group, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, press star one again.
Thank you. I'd now like to turn the call over to Ashley Schneider. Please go ahead.
Good morning.
Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1,995.
These forward-looking statements are based on assumptions and assessments made by pediatrics' management in light of their experience and assessment of historic trends, current conditions, expected future developments,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
